TSTickerStarGet alerts
Company alerts/LENZ
LENZ company alerts

LENZ updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for LENZ. Subscribe to LENZ alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for LENZ alertsView companies
Official-source feed

Recent LENZ alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

SEC filingSEC filing

LENZ 10-Q filed 2026-11-03 | Key takeaways

LENZ filed its 10-Q; the most relevant disclosure change is added Subsequent events - Strategic reorganization: On October 28, 2026, the board approved a strategic reorganization to prioritize consumer marketing, allocate capital to maximize sales growth, and reduce operating expenses, including decreasing headcount by approximately 75% to approximately 40 full-time emp. Customer concentration: Three wholesaler customers (anonymized) represented 38% of revenue; Three wholesaler customers (anonymized) represented...

Read source-backed brief
WebcastEarnings call webcast

LENZ Therapeutics: Telehealth and TV Ads Drive 50% Growth; CEO Transition Nuance

LENZ Therapeutics' Q3 2026 call centered on a decisive pivot toward a 'consumer-led' commercial model, following a quarter where telehealth and national TV advertising drove a 50% sequential increase in product revenue. Management provided critical color on the efficiency of the telehealth channel, which accounted for over half of incremental script growth and significantly compressed the sales cycle from weeks to days. While the CEO transition and a 50% reduction in projected 2027 operating expenses dominated t...

Read source-backed brief
EarningsOfficial company source

LENZ Therapeutics Reports Q3 2026 Financial Results with $2.6M Product Sales; Announces CEO Succession and Strategic Reorganization

LENZ Therapeutics reported Q3 2026 product sales of $2.6 million with over 38,000 paid prescriptions, representing approximately 50% and 51% growth over Q2 2026 respectively. Net loss for Q3 2026 was $31.0 million or $0.99 per share compared to net loss of $16.7 million or $0.59 per share in Q3 2025. The Company announced CEO succession with Eef Schimmelpennink transitioning effective December 1, 2026 and CFO Dan Chevallard assuming the role of Interim President and CEO, along with a strategic reorganization exp...

Read source-backed brief
Company newsOfficial company source

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

LENZ Therapeutics, Inc. reported fourth quarter and full year 2025 financial results and recent corporate highlights on March 24, 2026. The company had previously announced on January 7, 2026 that it expected fourth quarter 2025 preliminary unaudited financial results. Additional corporate updates include a Marketing Authorization Application submission to the European Medicines Agency for VIZZ, a commercialization partnership with Lunatus for the Middle East, and an NDA submission to MFDS in South Korea for pre...

Read source-backed brief